First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome

Palterer, Boaz; Vitiello, Gianfranco; Cammelli, Daniele

doi:10.4081/reumatismo.2017.923

Cited by 7 publications

(5 citation statements)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinically, anti-TIF-1 positive patients can be classified in two age groups: (1) younger than 40-year-old patients, with a classical DM at presentation and (2) older than 40-year-old patients, with cancer-associated myositis [ 70 ]. Solid tumors, like ovary, lung and breast cancer are the most commonly associated neoplasia, but hematologic disorders and malignancies have been described as well [ 79 ]. In general anti-TIF-1γ patients exhibit a hypo-myopathic DM with reduced prevalence of systemic involvement, namely ILD, Raynaud’s phenomenon and arthritis [ 80 ].…”

Section: Myositis-specific Autoantibodiesmentioning

confidence: 99%

Bench to bedside review of myositis autoantibodies

et al. 2018

View full text Add to dashboard Cite

Idiopathic inflammatory myopathies represent a heterogeneous group of autoimmune diseases with systemic involvement. Even though numerous specific autoantibodies have been recognized, they have not been included, with the only exception of anti-Jo-1, into the 2017 Classification Criteria, thus perpetuating a clinical-serologic gap. The lack of homogeneous grouping based on the antibody profile deeply impacts the diagnostic approach, therapeutic choices and prognostic stratification of these patients. This review is intended to highlight the comprehensive scenario regarding myositis-related autoantibodies, from the molecular characterization and biological significance to target antigens, from the detection tools, with a special focus on immunofluorescence patterns on HEp-2 cells, to their relative prevalence and ethnic diversity, from the clinical presentation to prognosis. If, on the one hand, a notable body of literature is present, on the other data are fragmented, retrospectively based and collected from small case series, so that they do not sufficiently support the decision-making process (i.e. therapeutic approach) into the clinics.

show abstract

Section: Myositis-specific Autoantibodiesmentioning

confidence: 99%

Bench to bedside review of myositis autoantibodies

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In the majority of these cases, PM/DM preceded hematologic malignancy onset - similar to what is seen in solid tumor literature [6]. MDS, however, has rarely been reported in connection with DM despite a known link between MDS and development of other autoimmune diseases like vasculitis and seronegative arthritis [7-10]. Palterer et al recently described a patient with anti-TIF1gamma antibody-positive DM diagnosed with low-risk MDS after an extensive workup for malignancy.…”

Section: Discussionmentioning

confidence: 59%

“…Palterer et al recently described a patient with anti-TIF1gamma antibody-positive DM diagnosed with low-risk MDS after an extensive workup for malignancy. MDS was stable without excess blasts and required no therapy; importantly, the disease course of DM was not discussed [10]. Case reports of DM associated with MDS are summarized in Table 1.…”

Section: Discussionmentioning

confidence: 99%

Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment

Lerman¹,

Richardson²

2019

Cureus

View full text Add to dashboard Cite

Dermatomyositis (DM) classically presents as a dyad of typical cutaneous findings and varying degrees of proximal muscle weakness. Interestingly, the development of DM may signal underlying malignancy, and numerous myositis-specific autoantibodies have been associated with this paraneoplastic phenomenon. Positivity for anti-TIF1gamma antibody, in particular, raises suspicion for cancer-associated DM. Here, we present an unusual case of anti-TIF1gamma antibody-positive DM that ultimately lead to the diagnosis of myelodysplastic syndrome (MDS). Importantly, topical treatment and chemotherapy targeting MDS resulted in a swift and remarkable amelioration of cutaneous disease.

show abstract

“…La anemia según su severidad se clasifica en leve, moderada y severa según el valor de la hemoglobina de 11-11.9g/L en mujeres y de 11-12.9g/L en varones, se recalca que el grado de severidad de la anemia depende del periodo de hospitalización que tenga el paciente, además de la gravedad de patologías precedentes de quién lo padezca (Velásquez et al, 2016). La anemia presente en el adulto mayor (mayor a 60 años) no es debido al envejecimiento propiamente sino principalmente a un déficit de hierro en la ingesta, que se desencadena en varias enfermedades como renales crónicas (Cappellini et al, 2017), respuestas inflamatorias por infecciones virales (VIH, hepatitis B y C) (Harding et al, 2020), bacterianas (tuberculosis pulmonar, meningitis) (Mortazavi-Moghaddam et al, 2022), infecciones crónicas del tracto urinario (Abou Heidar et al, 2019), infección pélvica crónica (Curry et al, 2019), inflamaciones crónicas asociadas a lupus eritematoso sistémico (Ostendorf et al, 2020), artritis reumatoidea (Chueh et al, 2020), enfermedades inflamatorias del intestino grueso (Joosten, 2018), enfermedades del tejido conectivo como dermatomiositis (Palterer et al, 2017), tumores malignos (Stauder et al, 2018), mieloma múltiple (Wildes y Campagnaro, 2017).…”

Section: Introductionunclassified

Síndrome anémico en la edad adulta tardía en una población de la sierra ecuatoriana

Manobanda-Lozada

Ramos

Razo

et al. 2022

GICOS

View full text Add to dashboard Cite

La anemia es el descenso de la concentración de hemoglobina e incapacidad de eritropoyesis para compensar la pérdida excesiva de eritrocitos. La población más vulnerable al síndrome anémico (SA) son personas mayores de 60 años, quienes representan alrededor del 12% del total de la población latinoamericana. El objetivo de esta investigación fue analizar la prevalencia del SA en adultos entre 60 a 75 años en 4 parroquias de la ciudad de Ambato en base a valores de hemoglobina (HGC), eritrocitos (RBC) y hematocritos (HCT), durante un periodo de 8 días (12-20 Jul 2022). Se utilizó un diseño descriptivo, transversal, de campo. Con razón de probabilidades (Odd Ratio) en base al Índice de Masa Corporal (IMC) de los pacientes, y la prevalencia de SA con respecto al número total de pacientes. La muestra de estudio fue de 52 de 100 pacientes geriátricos, y se determinó que, en 2 de los 4 sitios, hubo un paciente con nivel elevado de hematíes (6,06 106/Ul), y otro paciente con niveles superiores de HGB (19 g/dL) y HCT (59%), sin embargo, no se evidenció ningún caso de anemia debido a la ingesta adecuada en los alimentos consumidos por parte de la población establecida. La probabilidad de presentar SA en los cuatro sitios de estudio es de nula a muy baja, con una prevalencia de 0,045% incluyendo todos los pacientes.

show abstract

First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome

Cited by 7 publications

References 8 publications

Bench to bedside review of myositis autoantibodies

Bench to bedside review of myositis autoantibodies

Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment

Síndrome anémico en la edad adulta tardía en una población de la sierra ecuatoriana

Contact Info

Product

Resources

About